LA JOLLA, Calif. , Feb. 8, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Dan Chevallard , Chief Financial Officer of Regulus, will participate in a
LA JOLLA, Calif. , Dec. 19, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has initiated the first-in-human Phase I study of RGLS4326 and
Conference Call Today at 5:00 p.m. ET LA JOLLA, Calif. , Nov. 7, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today summarized recent events and reported financial
Conference Call and Webcast to Follow LA JOLLA, Calif. , Oct. 31, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide third quarter 2017
LA JOLLA, Calif. , Aug. 30, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present
LA JOLLA, Calif. , Aug. 8, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present
LA JOLLA, Calif. , July 25, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS) , a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the completion of its previously announced underwritten public offering of 50,600,000 shares of its common
LA JOLLA, Calif. , July 19, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at the price to the
